

It is noted that no rejection of claims 1, 4 and 6 was advanced, but these claims were listed as rejected on the face of the action. Thus, indication of the allowability of these claims is respectfully requested.

II. Rejection Under 35 U.S.C. §112, Second Paragraph

Claims 2, 3 and 5 are rejected under §112, second paragraph. The examiner again states that applicants have not complied with the sequence listing requirements by failing to refer to sequences referenced in the claims by their corresponding SEQ ID NO. Applicants again traverse.

The examiner's only rebuttal to the previous response is to repeat that sequences meeting the length requirements of 37 C.F.R. §1.821(a) are subject to provision in the form of a sequence listing, and reference by SEQ ID NO. This much is not disputed. However, *there are no sequences set forth in claims 2, 3 and 5*. They do not include "a string of particular ... amino acids." Thus, the mere reference to a segment of the RhoA protein by virtue of its position with respect to the whole molecule *clearly* does not fall within the purview of 37 C.F.R. §1.821 *et seq.*

However, purely in the interest of advancing the prosecution, applicants have canceled claims 2, 3 and 5. Withdrawal of the rejection is respectfully requested.

III. Rejoinder of Withdrawn Claims 7-10

Applicants again remind the examiner that claims 7-10 were withdrawn pursuant to an election of species requirement advanced in Paper No. 16, mailed May 10, 2000. Pursuant to 37 C.F.R. §1.141, applicants are entitled to consideration of these additional species at such time as

generic claim 1 is allowed. Applicants believe that claim 1 is now allowable, and respectfully request examination of withdrawn claims 7-10.

IV. Summary

In light of the preceding remarks, applicants respectfully submit that claims 1, 4, 6 and 7-10 are in condition for allowance, and an early indication to that effect is earnestly solicited. Should Examiner Scheiner have any questions regarding this response, she is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

Date: December 30, 2002

Fulbright & Jaworski, LLP
2400 One American Center
600 Congress Avenue.
Austin, TX 78701
512-536-3184

APPENDIX A: MARKED UP COPY OF AMENDED CLAIMS

4. (Amended) The peptide of claim [3, further comprising]1, wherein the peptide comprises the amino acid sequence Thr-Asp-Val-Ile-Leu-Met-Cys-Phe-Ser-Ile-Asp-Ser-Pro-Asp-Ser-Leu-Glu-Asn-Ile (SEQ. I.D. NO. 1).

6. (Amended) The peptide of claim [5, further comprising]1, wherein said peptide comprises the amino acid sequence Ile-Leu-Met-Cys-Phe-Ser-Ile-Asp-Ser-Pro (SEQ. I.D. NO. 2).

APPENDIX B: CLEAN COPY OF PENDING CLAIMS (UNOFFICIAL)

1. An isolated peptide of about 7 to 100 amino acid residues comprising a viral fusion protein binding domain of the RhoA protein.
4. The peptide of claim 1, wherein the peptide comprises the amino acid sequence Thr-Asp-Val-Ile-Leu-Met-Cys-Phe-Ser-Ile-Asp-Ser-Pro-Asp-Ser-Leu-Glu-Asn-Ile (SEQ. I.D. NO. 1).
6. The peptide of claim 1, wherein said peptide comprises the amino acid sequence Ile-Leu-Met-Cys-Phe-Ser-Ile-Asp-Ser-Pro (SEQ. I.D. NO. 2).
7. An isolated peptide of about 7 to 100 amino acid residues comprising a RhoA binding domain of the F glycoprotein of respiratory syncytial virus.
8. The isolated peptide of claim 7, further comprising amino acid residues 9 to 18 of the F1 subunit of the F glycoprotein of respiratory syncytial virus.
9. An isolated peptide of about 7 to 100 amino acid residues comprising a RhoA binding domain of the glycoprotein gp41 of the human immunodeficiency virus.
10. The isolated peptide of claim 9, further comprising amino acid residues 29-50 of HIV gp41.